Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10631419 | 0.84 | TSHR (0.68) | ALDH1A1SMN1; SMN2KDM4ETSHRMAPT | |
| SCHEMBL13977766 | 0.83 | GAA (0.68) | PTGS2GAAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2236676 | 0.83 | GAA (0.68) | PTGS2GAAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL5446847 | 0.82 | TSHR (0.73) | GAAALDH1A1SMN1; SMN2KDM4ETSHR | |
| SCHEMBL5724515 | 0.82 | TSHR (0.56) | PTGS2GAAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL5446840 | 0.81 | PTGS2 (0.59) | PTGS2GAAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL14518056 | 0.79 | L3MBTL1 (0.63) | PTGS2GAAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL9192465 | 0.78 | PTGS2 (0.55) | PTGS2GAAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2831390 | 0.77 | PTGS2 (0.67) | PTGS2GAAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL28784413 | 0.76 | ALDH1A1 (0.59) | GAAALDH1A1SMN1; SMN2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873674-B2 | C-Rel inhibitors and uses thereof | CORNELL UNIVERSITY (US) | 2018-01-23 | — | — | US | disclosed |
| US-20150218109-A1 | C-REL INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| WO-2014047232-A2 | C-REL INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2014-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218109-A1 | C-REL INHIBITORS AND USES THEREOF | REL, NCOR1, CXCR4 | PTGS2 2958/4885GAA 4206/4885ALDH1A1 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.